Navigation Links
NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
Date:10/17/2011

ward for NeoStem into clinical development and the furtherance of our mission to develop a product portfolio of cell therapy products that leverage the body's natural abilities to heal and fight disease. We believe that AMR-001 bridges the gap between cell therapy's roots in bone marrow transplantation and cell therapies of the future. "

About NeoStem, Inc.

NeoStem is a leader in the development and manufacturing of cell therapies. The Company's strategic combination of revenues with manufacturing through its subsidiary, Progenitor Cell Therapy, LLC and global reach has positioned the company for advances in the cell therapy industry. The acquisition of Amorcyte, Inc. positions NeoStem to achieve its mission of capturing the paradigm shift to cell therapy. NeoStem is also pursuing a T-cell therapeutic with potential in a range of auto-immune conditions and development of its VSEL™ Technology platform. For more information on NeoStem, please visit www.neostem.com.

About Amorcyte

Amorcyte develops cell therapy products to treat cardiovascular disease. Its lead product, AMR–001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase 1 clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte was founded by Andrew Pecora, M.D., Chief Innovations Officer, Professor and Vice President of Cancer Services at the John Theurer Cancer Center at Hackensack University Cancer Center, with initial investment by Novitas Capital and Colt Ventures. For more information, please visit: www.amorcyte.com.

Forward-Looking Statements

This press release contains forward-looking statements within t
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
2. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
3. NeoStem, Inc. to Enter the Regenerative Medicine Market in Asia
4. NeoStem Completes $500,000 Private Placement With Strategic Investor
5. NeoStems New York City Adult Stem Cell Collection Center Has Opened and Begun Collections
6. NeoStem Receives Notice of Noncompliance from NYSE Alternext US
7. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
8. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
9. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
10. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
11. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... The report provides qualitative insights on key market ... the market, in order to provide information about the ... market sizes for each sub-segment of the market and ... also includes analysis of the company profiles of the ... performances, product portfolios, and developments of each company. The ...
(Date:11/27/2014)... First articles published now ... Elsevier , a world-leading provider of scientific, technical ... announce the launch of a new journal: ... The launch of Extreme Mechanics Letters is ... of applied sciences such as micro and nanotechnologies, biotechnologies, ...
(Date:11/26/2014)... 26, 2014 The report on the ... segments the concerned market for revenue forecasts and market ... CAGR of 51.9% from 2013 to 2018. At the ... value of $1,415.6 million by 2018. , Browse through ... TOC for information about the market segmentation and in-depth ...
(Date:11/26/2014)... -- The announced sales of three healthcare units within ... expand in non-healthcare areas, says Kalorama Information. Siemens hasn,t ... says that  Siemens is the third largest company in ... IVD market , with 5.5 billion in IVD revenues ... likely affect IVD market shares.  Siemens ...
Breaking Biology Technology:Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Product Suite and Addresses Sample Preparation Bottlenecks -HOPKINTON, ... (Nasdaq: CALP ), a leading provider ... life sciences research, today launched the Zephyr Genomics ... for molecular biology applications. The inclusion of pre-installed ...
... Double Helix Consulting US (DHC US), headed by ... of highly experienced strategic pricing, reimbursement and market ... industry as well as strong commercial, governmental and ... to clients in the pharmaceutical, biotechnology and medical ...
... 26 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE Alternext ... in China, today,announced its wholly owned subsidiary, ... approval from China,s Ministry of Agriculture to,conduct ... animal rabies,vaccine with independent intellectual property rights. ...
Cached Biology Technology:Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling 2Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling 3London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 3Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 4
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug Association ... regulatory agencies will speak and at least seven more will ... at the Omni Shoreham Hotel in Washington D.C. ... again to have significant support from the regulatory agencies in ... Europe in our effort to help advance the ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... at the Universities of Bristol, Florence, and Western Australia, might ... with the disorder. The faces we see in the ... points in a face-space, said Elizabeth Pellicano of the University ... average, or most typical, face, with more distinctive faces lying ...
... by investigators at St. Jude Childrens Research Hospital provide ... or Gleevec, which has revolutionized the treatment of chronic ... of a particularly aggressive form of acute lymphoblastic leukemia ... activity of a specific molecule, a strategy aimed at ...
... It appears that chemical warfare has been around a ... about 100 million years, give or take a little. ... has identified a soldier beetle, preserved almost perfectly in amber, ... fight off an attacker when an oozing flow of sap ...
Cached Biology News:Children with autism don't adapt as readily to unfamiliar faces 2St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia 2Amber specimen captures ancient chemical battle 2Amber specimen captures ancient chemical battle 3
... Since the Flp-In System creates isogenic ... equivalent levels of the protein of ... in Figure 3. In this experiment ... (CAT) was subcloned into pcDNA5/FRT and ...
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
SHEEP ANTI BOVINE LACTOPEROXIDASE...
Fast, sensitive quantitation of total MEK 1/2 concentration....
Biology Products: